在癌症患者中优化智能手机心理治疗抑郁症状:使用分散的多中心随机临床试验 (J-SUPPORT 2001研究) 的多相优化策略
Tatsuo Akechi1,2, Toshiaki A Furukawa3, Hisashi Noma4
1Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Psychiatry and clinical neurosciences
|March 12, 2024
概括
这项研究测试了用于癌症患者抑郁症的智能手机应用程序,发现特定的认知行为治疗技能没有显著的益处. 需要进一步的研究,以提供基于证据的建议,针对癌症患者的智能手机心理治疗.
科学领域:
- 在瘤学瘤学.
- 精神病学是一个精神病学.
- 数字健康数字健康
背景情况:
- 癌症患者经常经历抑郁症状,影响生活质量和增加医疗保健成本.
- 虽然心理治疗是癌症相关抑郁症的药物治疗的首选,但需要可访问和有效的干预措施.
- 基于智能手机的干预提供了一个可扩展的方法,为癌症患者提供心理支持.
研究的目的:
- 开发和评估一个有效的智能手机心理治疗组件,以减少癌症患者的抑郁症状.
- 在智能手机应用程序中评估特定认知行为疗法技能的增益效应.
主要方法:
- 一个分散的,多中心的,随机的试验,涉及359名20岁及以上的癌症患者.
- 参与者被随机分配,通过智能手机应用程序接受心理教育加上各种行为激活组合,自信训练和解决问题的技能.
- 主要结局是患者健康问卷-9 (PHQ-9) 评分从基线到第8周的变化.
主要成果:
- 所有参与者 (-1.41分) 均观察到抑郁症状 (PHQ-9分) 的显著减少.
- 然而,在接受不同组合认知行为疗法技能的组之间,没有发现症状减轻的统计学意义上的差异.
- 该研究实现了高的随访率,99%的参与者在第8周提供了结果数据.
结论:
- 在智能手机干预中,添加特定的认知行为疗法组件 (行为激活,自信训练,解决问题) 并没有显著提高抑郁症症状的减少.
- 目前的发现不支持基于证据的建议,针对癌症患者的特定智能手机心理治疗组件.
- 需要进一步的研究,以优化数字心理健康干预措施对这一群体.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Antidepressant Drugs: MAOIs and Other Agents
229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229


